Of most interest, PPARγ antagonists (GW9662) play a role in macrophage differentiation, regulating the expression of apoptosis-phagocytosis genes in apoptotic cells (Seargent et al., 2004; Majai et al., 2007) and inhibits growth of breast tumour cells (Seargent et al., 2004), which support a PPARγ-mediated transrepression mechanism, previously shown to be responsible for the anti-inflammatory effects of PPARγ ligands through the NF-κB signaling pathway (Pascual et al., 2005). Here, PPARG is linked to breast neoplasm.